Lung cancer treatment in Turkey should begin with confirmation of the diagnosis and stage—not with the selection of a hospital, operation or medicine. The appropriate plan depends on the pathological subtype, extent of disease, molecular profile, PD-L1 result where relevant, previous treatment, respiratory reserve, other medical conditions and the patient’s current symptoms.
No single treatment is suitable for every person with lung cancer. One patient may benefit from surgery followed by additional treatment, while another may require stereotactic radiotherapy, chemoradiotherapy, targeted therapy, immunotherapy, chemotherapy or a carefully planned combination. Even patients who appear to have the same stage may follow different pathways because their tumours have different biological features or their overall health differs.
This guide explains how specialists assess lung cancer, when molecular testing may change the treatment sequence and how surgery, radiotherapy and systemic treatment are used. It also explains which records international patients should send before travelling and how follow-up can be coordinated after they return home. All final decisions must be made by licensed clinicians after reviewing the complete case.
A responsible treatment plan is developed after the medical team reviews the pathology, original imaging, documented stage, respiratory fitness, relevant comorbidities, previous treatment and available biomarker results. If any of these elements is missing or uncertain, the first recommendation may be to complete the diagnosis rather than begin treatment immediately.
The specialists involved can include a medical oncologist, thoracic surgeon, radiation oncologist, pulmonologist, radiologist, nuclear-medicine physician, pathologist and molecular-diagnostics team. In complex cases, their findings may be discussed at a multidisciplinary tumour board.
An online review of reports, DICOM images and existing test results can often clarify what should happen next. It may identify missing information, determine the most relevant specialist and help avoid unnecessary travel. However, a records review cannot always replace a physical examination, current imaging, pulmonary-function testing or a new biopsy. The written proposal should therefore distinguish between conclusions supported by the available evidence and decisions that remain conditional on further assessment.
Non-small cell lung cancer, or NSCLC, includes adenocarcinoma, squamous-cell carcinoma and several less common pathological subtypes. It accounts for most lung-cancer diagnoses, but it is not a single disease with one standard treatment pathway.
Depending on the stage and tumour biology, treatment can involve surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy or a combination of these approaches. Molecular testing is particularly important in selected NSCLC cases because an actionable alteration may influence the choice or sequence of systemic treatment. The required tests depend on the histological subtype, stage, available tissue and current clinical guidance.
Small cell lung cancer, or SCLC, behaves differently and is generally divided clinically into limited-stage and extensive-stage disease. It often grows and spreads rapidly, so systemic treatment and radiotherapy usually have a more prominent role than surgery.
The NSCLC pathway should not be applied automatically to SCLC. Brain imaging, the distribution of disease, the patient’s fitness and the urgency of treatment all influence the plan. Surgery is considered only in uncommon, carefully staged early cases.
The pathology report should identify the cancer type and, where possible, its subtype. For a complex, unusual or uncertain case, the written report alone may not provide enough information for a new medical team to confirm the diagnosis. A specialist pathologist may need to review the original glass slides, paraffin blocks or validated digital-pathology material.
This review can be especially valuable when the sample is small, the terminology is unclear, the clinical behaviour appears inconsistent with the diagnosis or different hospitals have offered conflicting interpretations. If the classification changes, the revised diagnosis should be documented in a formal report by a qualified pathologist.
A biopsy must provide enough representative material for diagnosis while exposing the patient to the lowest reasonable risk. Depending on the tumour’s location and the patient’s condition, sampling may involve bronchoscopy, endobronchial ultrasound-guided biopsy, CT-guided needle biopsy, pleural-fluid analysis or a surgical procedure.
The safest biopsy is not necessarily the one that is easiest to schedule. The medical team must consider whether the specimen will answer the diagnostic question and preserve enough material for relevant biomarker testing. If suitable tissue already exists, it should be assessed before an invasive procedure is repeated automatically.
A new biopsy may be considered when the original material is insufficient, the diagnosis remains uncertain, the disease has changed after treatment or the current tumour biology may differ from that shown by an old sample. It may also be necessary when clinically important molecular information cannot be obtained reliably from the available tissue.
This is an individual clinical decision. International patients should not assume that every test must be repeated after arrival, nor should they expect an old specimen to remain adequate in every situation.
Staging may include contrast-enhanced CT, PET-CT and brain MRI when clinically appropriate. Each examination answers a different question, and the required combination depends on the suspected stage, pathological subtype, symptoms and proposed treatment.
Specialists generally need the original images in DICOM format, not only a written report, screenshot or mobile-phone photograph. Reviewing the full image series allows the radiologist, surgeon and radiation oncologist to assess tumour position, lymph nodes, possible metastatic sites and the relationship between the tumour and nearby structures.
PET-CT can identify areas that require closer investigation, but increased uptake does not prove that every site contains cancer. Inflammation and infection can also produce abnormal findings, and selected lesions or lymph nodes may require pathological confirmation.
Accurate lymph-node staging can change whether surgery, definitive radiotherapy or a multimodal approach is recommended. Suspicious mediastinal nodes may require sampling with endobronchial ultrasound, mediastinoscopy or another appropriate technique. Imaging and biopsy findings should be interpreted together.
Stage describes the cancer, but it does not describe the whole patient. Assessment may include pulmonary-function tests, performance status, blood tests, nutrition, kidney and liver function and, when indicated, cardiac evaluation.
Technical resectability and medical fitness are separate questions. A tumour may be anatomically removable while the proposed operation presents excessive risk because of limited lung or heart reserve. Conversely, a patient who is not suitable for surgery may still have potentially effective radiotherapy or systemic options.
Selected NSCLC tumours carry molecular alterations that may create a clinically relevant targeted-treatment option. Representative categories include EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK and HER2. The appropriate panel is not identical for every patient and should be selected according to histology, stage, available material, previous treatment and current guidelines.
A detected alteration does not automatically mean that a particular medicine is suitable. The oncologist must determine whether the result is technically reliable, whether the alteration is actionable in that clinical setting and whether an approved or evidence-supported treatment is appropriate for the patient.
Test quality also matters. The report should identify the specimen, laboratory method, genes or alterations assessed, analytical limitations and clinical interpretation. A narrow panel may not answer the same question as broader next-generation sequencing. Equally, broader testing is not a substitute for a clear clinical reason for ordering it. Recmed’s NGS cancer testing guide explains tissue and liquid biopsy in more detail.
PD-L1 testing may help inform decisions about immunotherapy in selected patients. However, it does not independently determine the whole treatment plan and cannot guarantee that a tumour will respond. The result must be interpreted with the cancer subtype, stage, molecular findings, treatment setting, symptoms and overall health.
A high result does not eliminate the need to check for relevant driver alterations, and a low or negative result does not exclude every immunotherapy-containing regimen. Detailed eligibility and safety decisions belong with the treating oncology team. For a fuller explanation, see Recmed’s immunotherapy eligibility and testing guide.
Tissue usually provides information about both tumour structure and molecular features. Blood-based testing, often called liquid biopsy, analyses tumour-derived material circulating in the bloodstream and may be useful when tissue is unavailable, unsafe to obtain or inadequate for molecular analysis.
Liquid biopsy can also help in selected cases of progression or suspected treatment resistance. Its principal limitation is that some tumours release little detectable material into the blood. A negative result therefore does not always exclude an actionable alteration. When clinically appropriate, tissue testing may still be recommended after an uninformative blood result.
A multidisciplinary review brings pathology, radiology, molecular results, respiratory fitness and previous treatment into one clinical discussion. It is particularly useful when potentially operable stage III disease, uncertain lymph-node involvement, limited metastatic disease or competing local and systemic options make the sequence of treatment unclear.
It may also help when one team recommends surgery while another recommends chemoradiotherapy, or when a previous treatment has stopped working and several next steps appear possible. The purpose is not simply to collect multiple opinions; it is to resolve specific questions using the same complete evidence.
Not every routine case requires a formal tumour board. A straightforward clinical question may be addressed by the relevant specialist, supported by pathology or radiology review. When multidisciplinary discussion is used, the patient should receive a written recommendation that identifies the records reviewed, the agreed diagnosis and stage, remaining uncertainties, the proposed treatment sequence and any tests required before a final decision.
Surgery is a central option for appropriately selected patients with localised NSCLC. Before recommending it, the team must assess tumour position, lymph nodes, possible metastatic disease, lung function and general surgical risk.
The operation is only one part of the pathway. Final surgical pathology can reveal features that change the documented stage or influence whether additional treatment should be discussed. Depending on the stage, pathology, molecular profile and current evidence, selected patients may be considered for treatment before surgery or for chemotherapy, targeted therapy, immunotherapy or another strategy after surgery. These therapies are not required in every early-stage case.
For selected patients with medically inoperable early-stage disease, stereotactic body radiotherapy can deliver highly focused treatment to the tumour while limiting exposure to surrounding tissue. It may also be considered by patients who decline surgery after a balanced specialist discussion.
Suitability depends on tumour size and position, proximity to critical structures, previous radiotherapy, lung function and normal-tissue constraints. A central tumour may require a different schedule or approach from a small peripheral lesion. The diagnosis and stage should be sufficiently established before definitive treatment begins.
Stage III NSCLC is highly varied. Some patients have disease that may be managed with surgery as one part of a multimodal plan. Others have unresectable disease for which definitive chemoradiotherapy may be considered, followed by further treatment when clinically indicated.
The distinction cannot be made from the stage number alone. The location and number of involved lymph nodes, relationship to major structures, tumour volume, respiratory reserve and molecular features all matter. Treatment may involve systemic therapy before a local treatment, surgery followed by additional therapy, or concurrent or sequential chemoradiotherapy. No one sequence is universally superior for every stage III presentation.
In metastatic NSCLC, the first systemic decision should consider actionable molecular alterations, PD-L1, histology, previous treatment, disease burden, symptoms, organ function and general fitness. For a patient with a clinically actionable driver alteration, a relevant targeted therapy may be prioritised. For other patients, immunotherapy, chemotherapy or a combination may be appropriate.
Local treatment can still have a role. Radiotherapy may relieve pain, bleeding, airway pressure or neurological symptoms. Selected patients with a limited number of metastatic sites may be considered for focused local treatment within a broader systemic plan. Such decisions require careful selection and should not be presented automatically as curative.
A wedge resection removes the tumour with a limited surrounding margin. A segmentectomy removes an anatomical segment of the lung, while a lobectomy removes one lung lobe. A pneumonectomy removes an entire lung and is reserved for situations in which adequate cancer surgery cannot be achieved with a smaller resection. Selected central tumours may require a sleeve resection or another complex procedure.
The chosen operation depends on tumour size and position, lymph-node status, lung function and oncological safety. The smallest operation is not automatically the safest or most effective, and the largest operation is not automatically more thorough. The goal is appropriate cancer control while preserving as much functional lung as is safely possible.
Selected operations can be performed using video-assisted thoracic surgery, known as VATS, or robotic-assisted techniques. Other cases require an open thoracotomy because of tumour anatomy, previous surgery, adhesions, major-vessel involvement or the need for complex reconstruction.
A minimally invasive label should not be used as a substitute for clinical judgement. Surgeon experience, systematic lymph-node evaluation and the ability to complete an oncologically appropriate resection are more important than marketing terminology. Conversion from a minimally invasive approach to open surgery can sometimes be the safest decision rather than a treatment failure.
Systematic assessment of the hilar and mediastinal lymph nodes helps determine the final pathological stage. The resected tumour is also examined for subtype, size, margins, lymphovascular invasion and other relevant features. Because these findings may differ from the preoperative estimate, the postoperative treatment recommendation should be based on the final pathology rather than on imaging alone.
Recovery includes pain control, breathing exercises, early mobilisation and chest-tube management. Potential complications include prolonged air leak, infection, bleeding, heart-rhythm disturbance, blood clots and cardiopulmonary problems.
Length of stay and readiness to fly cannot be predicted from the operation name alone. They depend on the extent of surgery, lung function, complications, mobility, oxygen requirements and the availability of safe follow-up after discharge.
Stereotactic body radiotherapy, often abbreviated as SBRT or SABR, delivers high-precision radiation therapy over a limited number of sessions. It is used for selected early-stage tumours when surgery is unsuitable and may also be considered for certain limited metastatic sites.
Treatment near central airways, the oesophagus, spinal cord or other sensitive structures requires particular care. Previous radiotherapy can further limit what can be delivered safely.
Radiotherapy may be used as definitive local treatment, after surgery in selected circumstances, or to control symptoms from primary or metastatic disease. Some courses use conventional fractionation, while others use fewer, larger fractions. The appropriate schedule depends on the clinical objective, tumour location and normal-tissue tolerance.
Planning normally includes a simulation scan, reproducible positioning and computerised dose calculation. The team maps the treatment target and nearby lungs, heart, oesophagus, spinal cord and other structures so that exposure can be controlled as far as reasonably possible.
Radiotherapy and chemotherapy may be delivered concurrently or sequentially. Concurrent treatment can be more intensive and is not suitable for every patient. Tumour volume, stage, pulmonary reserve, organ function, nutritional status and general fitness influence the decision.
The recommended approach should identify the treatment objective, expected schedule, monitoring plan and arrangements for managing swallowing difficulty, lung inflammation, fatigue, blood-count changes and other possible effects.
Chemotherapy can be used before surgery, after surgery, with radiotherapy or as part of treatment for advanced disease. The regimen and schedule depend on the pathological subtype, stage, treatment objective, kidney and liver function, blood counts, previous therapy and patient fitness.
The plan should also explain how response and toxicity will be monitored. Dose changes, delays or supportive treatment may be required; these decisions do not necessarily mean that treatment has failed.
Targeted therapy is designed to act on a particular molecular alteration or pathway. It requires a validated result and a clinical indication in which the treatment is supported. The presence of a mutation on a report does not automatically establish eligibility, especially when the alteration is uncommon, technically uncertain or detected outside the setting in which a therapy is used.
Immunotherapy may be used alone or with chemotherapy for selected patients, and it can also have a role in certain earlier-stage settings. Selection can involve PD-L1, molecular findings, stage, prior therapy, autoimmune history, transplant status and general health.
Because immune activation can affect healthy organs, new respiratory, gastrointestinal, skin, endocrine, liver, neurological or cardiac symptoms should be reported promptly. Patients returning home need a clear contact and escalation plan.
Monitoring may include clinical review, blood tests and scheduled imaging. Radiological findings must be interpreted with symptoms, treatment timing and the therapy used. Apparent enlargement, stable disease or a mixed response can require specialist review rather than an automatic decision based on one measurement.
Treatment may change because of progression, unacceptable toxicity, a newly identified biomarker, altered patient priorities or completion of the planned course.
Limited-stage SCLC is usually treated with systemic therapy and thoracic radiotherapy when the patient is fit enough. The timing of radiotherapy and whether treatment is concurrent or sequential depend on disease extent, organ function, symptoms and tolerance.
Surgery is considered only in uncommon, carefully staged early cases, generally after thorough lymph-node and distant-disease assessment. Even when surgery is used, systemic treatment remains an important part of the plan.
Systemic treatment is the main approach for extensive-stage disease. Radiotherapy may be added selectively for thoracic control, troublesome symptoms or particular metastatic sites. The exact regimen and sequence should reflect current approvals, clinical guidance and the patient’s condition rather than a fixed package.
Brain assessment is important because SCLC has a recognised tendency to involve the brain. MRI may be used at diagnosis and during follow-up where appropriate.
Specialists may discuss MRI surveillance, cranial radiotherapy or another strategy according to disease stage, response, age, cognitive concerns and access to reliable follow-up. Preventive cranial treatment should not be presented as mandatory for every patient; the benefits and risks require an individual discussion.
A lung cancer second opinion can be valuable when important parts of the diagnosis or treatment sequence remain uncertain. It may be particularly useful when:
A second opinion does not necessarily produce a different recommendation. In many cases, it confirms that the original plan is appropriate. That confirmation can still be useful, especially before a major operation, a complex radiotherapy course or a change to systemic treatment.
For the review to be meaningful, the specialist should receive more than a short medical summary. Pathology records, original imaging, molecular results and the complete treatment history may all influence the conclusion. If critical information is missing, the opinion should be described as preliminary rather than definitive. Recmed’s cancer second-opinion guide explains the records process in detail.
A well-organised medical file helps the reviewing team understand the diagnosis, stage and previous treatment without unnecessary delay. The exact documents required vary by case, but the initial package should generally include:
Written radiology reports are useful, but they do not replace the original images. DICOM files allow the radiologist or treating specialist to review the scans directly, compare studies and assess findings that may influence staging or treatment planning.
Separate documents into clearly named folders such as “Pathology,” “Imaging,” “Molecular Tests,” “Treatment” and “Blood Tests.” Use dates in year-month-day format so that files sort chronologically. A one-page timeline can help the reviewer understand when the diagnosis was made, which treatments were given and when progression or complications occurred.
Send complete documents rather than cropped screenshots or photographs of selected pages. Records should be transferred through a confirmed secure channel, with the patient’s consent and in accordance with applicable data-protection requirements.
An initial review can often begin before the patient travels. Depending on the case, a specialist may be able to assess pathology reports, DICOM imaging, previous treatment records, molecular results and current clinical information remotely.
This pre-travel review may help determine:
Important limitation: A remote review can identify missing tests and guide the next discussion, but it cannot always replace pathology confirmation, review of original imaging, a physical examination, current laboratory testing, cardiopulmonary assessment, anaesthetic evaluation or a new biopsy.
Patients who are medically unstable, rapidly deteriorating or experiencing urgent symptoms should obtain immediate care where they are. Severe breathlessness, substantial coughing of blood, confusion, seizures, new weakness, severe chest pain or fever during cancer treatment should not be managed by waiting for international travel.
The first step is an administrative review of the submitted documents. Its purpose is to identify missing reports, images or treatment details. It is not a diagnosis, treatment recommendation or confirmation that the patient is eligible to travel.
The case should be matched according to the clinical question, lung-cancer subtype and treatment being considered. A potentially operable tumour may require input from a thoracic surgeon, while an uncertain systemic-treatment plan may require a medical oncologist with relevant lung-cancer experience.
The selected clinician reviews the available information and determines whether additional pathology, radiology or multidisciplinary assessment is appropriate. Complex cases may benefit from discussion by several disciplines, but not every routine case requires a formal tumour board.
If the patient is considered for further assessment or treatment, the medical provider should prepare a written proposal. Confirmed services should be distinguished from tests or treatments that remain conditional on examination, pathology review or new results. The estimate should state clearly what is and is not included.
Flights and accommodation are best arranged after the treating institution has reviewed the essential records. The team should clarify the expected duration of assessment, which original materials must be brought and whether the patient is medically fit to fly.
Before returning home, the patient should receive an English-language medical summary, treatment records, medicine list, follow-up schedule, warning signs and contact information. Where possible, the Turkish team and the patient’s home-country oncologist should agree on how monitoring and urgent complications will be handled.
Patients travelling from Nigeria, Ghana, Kenya, Uganda, Sierra Leone, South Africa and other English-speaking countries should ideally begin with a records review before spending money on flights, accommodation or visa-related arrangements. This records-first approach is also appropriate for patients travelling from the United Kingdom, Ireland, the United States, Canada, Australia, New Zealand and other regions.
Complete pathology, original DICOM imaging, molecular-test results and treatment records can help the specialist identify which information is already reliable and which investigations may need to be repeated. Not every test must automatically be performed again in Turkey. Repetition should have a clear clinical reason, such as outdated imaging, inadequate tissue, an uncertain diagnosis or a result that could change treatment.
Before arranging lung cancer treatment in Turkey for international patients, the patient or family should confirm:
Treatment planning should not assume that follow-up will always take place in Turkey. A practical plan must consider access to blood tests, imaging, medicines, emergency care and oncology expertise in the patient’s home country. The patient should travel with enough current medication and a written list of prescriptions, allergies and important medical conditions.
A family member may help organise documents, but medical information should only be shared with the patient’s consent or through an authorised representative. No coordinator or clinic can responsibly promise treatment eligibility before a qualified medical team has reviewed the case. Visa approval, travel arrangements and medical acceptance are separate matters.
There is no responsible single package price for lung cancer treatment before the patient’s diagnosis, stage and proposed treatment have been reviewed. Two patients with the same general diagnosis may require very different investigations and treatment pathways.
The overall cost may be affected by:
A written estimate should distinguish between confirmed, optional and conditional services. For example, a biopsy or additional molecular test may be required only if existing material is inadequate. Surgery-related estimates should explain whether they include the surgeon, anaesthesia, hospital stay, pathology and routine postoperative care.
Patients should compare like with like. A lower headline price may exclude medicines, pathology, radiotherapy planning, intensive care or complication management. Cost should be considered alongside the qualifications of the treating team, clarity of the proposed plan, continuity of care and medical justification for each service. Recmed’s general cancer-treatment guide provides broader information about planning and costs.
Some patients can continue all or part of their treatment in their country of residence. This depends on the availability of the prescribed medicine, suitable monitoring, oncology expertise and the ability to follow the same clinical protocol safely.
Before departure from Turkey, the patient should receive a written handover covering:
The home-country oncologist should have enough information to understand the reasoning behind the plan. Where possible, questions between the two medical teams should be resolved before the next treatment is due.
Continuity is particularly important when treatment can cause delayed complications. Immune-related adverse effects, for example, may arise after the patient has returned home or even after treatment has ended. The patient should inform every treating doctor about previous cancer medicines and should not attempt to manage serious adverse effects without medical assessment.
Warning signs in a proposal include:
A stronger proposal should name the responsible specialists, identify the records reviewed, explain the clinical reasoning, acknowledge uncertainty and list any information still required. It should also provide an itemised estimate and a plan for follow-up after the patient returns home.
Patients should be cautious when a particular technology is promoted as automatically superior. Robotic surgery, advanced radiotherapy and broad molecular panels can be valuable in appropriate cases, but their use should follow a clinical indication rather than marketing terminology.
Recmed Medical Travel is an Istanbul-based medical-travel coordination company. Depending on the patient’s needs and the instructions of the treating clinicians, coordination may include:
Recmed does not diagnose lung cancer, prescribe medicines, determine whether a patient is suitable for a particular treatment or guarantee a medical outcome. All diagnostic and treatment decisions are made by licensed physicians and medical institutions after reviewing the patient’s clinical information.
Patients can send their medical records for an initial completeness check before making travel arrangements. The public Recmed doctor directory includes medical oncology, radiation oncology and chest-surgery specialists, while the final specialist match should depend on the individual clinical question.
Sometimes urgent symptoms or rapid disease progression require treatment decisions before all test results are available. In other situations, waiting for clinically relevant molecular information may prevent the patient from starting a treatment that is not the most appropriate first option. Histology, stage, symptoms and clinical stability all affect this decision. The treating oncologist must determine whether waiting is medically safe.
It may be enough for an initial review, but not always for a definitive conclusion. If the diagnosis is unusual, the terminology is unclear or treatment depends on a precise subtype, the reviewing pathologist may request original slides, paraffin blocks or suitable digital pathology images. Additional tissue may also be needed for molecular testing.
Yes, whenever they are available. Written reports summarise the original interpretation, but they do not allow another specialist to inspect the images directly. DICOM files preserve the full imaging study and are more useful than screenshots, phone photographs or selected image files.
A preliminary opinion may often be prepared from complete records. However, a final plan may require physical examination, updated imaging, pathology review, pulmonary testing or a new biopsy. Remote review should not be described as final medical clearance when essential clinical information is still missing.
It can be considered in selected patients, but stage III lung cancer includes several very different clinical situations. Tumour location, lymph-node involvement, respiratory fitness and the possibility of complete resection all matter. A multidisciplinary review is usually important when surgery and definitive chemoradiotherapy are competing options.
Surgery is not routine treatment for most stage IV lung cancers. Selected patients with limited metastatic disease may be considered for local treatment as part of an individual multidisciplinary plan. The purpose and expected benefit must be explained clearly and should not be presented as universally curative.
Neither is automatically better for every patient. Targeted therapy requires a validated actionable alteration and a treatment indication relevant to the cancer type and clinical setting. Chemotherapy remains important in many lung-cancer pathways. The appropriate sequence depends on the tumour’s biology, stage, previous treatment and the patient’s condition.
No. PD-L1 can inform treatment selection in certain settings, but it does not guarantee a response. The cancer subtype, stage, molecular findings, previous treatment, general health and planned combination of therapies also influence the decision.
A blood-based liquid biopsy can be useful when tissue is unavailable, insufficient or unsafe to obtain. It may identify molecular alterations relevant to treatment. However, it does not always provide the pathological diagnosis, and some tumours release little DNA into the blood. A negative result does not necessarily exclude an actionable alteration, so tissue testing may still be recommended.
There is no single duration. A consultation and records review may require a short visit, while biopsy, surgery, radiotherapy or management of complications may require substantially longer. The expected stay should be estimated only after the clinical team has reviewed the case and identified the likely pathway.
Often it can, provided the prescribed medicines, monitoring and clinical expertise are available. The Turkish team and home-country oncologist should agree on the protocol, laboratory schedule, imaging plan, toxicity management and emergency contacts before transfer of care.
Seek urgent local medical care for severe or rapidly worsening breathlessness, substantial coughing of blood, severe chest or upper-back pain, facial or neck swelling with breathing difficulty, confusion, a seizure, new weakness or paralysis, severe headache, vision change, fever during cancer treatment or a sudden deterioration in general condition. New severe back pain with limb weakness, numbness or bladder or bowel dysfunction also requires emergency assessment. Do not wait for an international appointment or flight when urgent care is needed.
If you are considering lung cancer treatment in Turkey, begin by sending available pathology reports, imaging reports and DICOM files, treatment history, molecular results, recent blood tests and a concise description of current symptoms.
The initial purpose is to determine whether the documentation is sufficiently complete, which licensed specialist is most appropriate to review it and whether further information is needed before travel is considered. Medical records should be transferred through a confirmed secure channel and with the patient’s consent.
A records check does not confirm a diagnosis, guarantee treatment acceptance or promise that the existing plan will change. The responsible medical team must decide whether an online review is sufficient, whether new testing is required and whether the patient is medically fit to travel.
Request a Lung Cancer Case Review
This article provides general information and is not medical advice, a diagnosis or an individual treatment recommendation. The appropriate pathology review, staging investigations, molecular tests, treatment sequence and assessment of fitness to travel must be determined by licensed clinicians who have reviewed the patient’s complete medical information.
Do not start, stop, delay or change cancer treatment on the basis of this article. Patients with urgent or rapidly worsening symptoms should seek immediate medical care where they are rather than waiting for an international consultation or travel.
Recmed Medical Travel coordinates international medical services. It does not diagnose disease, prescribe treatment, determine treatment eligibility or guarantee results.